Cannabis Watch: Cannabis stocks tumble as analyst tells investors to brace for more weak earnings

Cannabis stocks fell across the board Wednesday, led by the big Canadian licensed players, after an analyst said earnings expectations are unrealistic and told investors to brace for more bad news. Read More...

Cannabis stocks fell across the board Wednesday, led by the big Canadian licensed players, after an analyst said earnings expectations are unrealistic and told investors to brace for more bad news.

MKM Partners analyst Bill Kirk outlined his forecasts for when companies will report positive EBITDA, or earnings before interest, taxes, depreciation and amortization, a metric that is more of a measure of cash flow than actual profit.

Even on that basis, Kirk said he expects market leader Canopy Growth CGC, -2.98% WEED, -2.67% will not be EBITDA positive until the first quarter of 2022, a full year later than the current consensus estimate. For Aurora Cannabis ACB, -3.88% ACB, -4.23%, the most widely held stock, Kirk expects positive EBITDA by the first quarter of 2021, compared with the current consensus of the third quarter 2020.

For Tilray Inc. TLRY, -4.76%, his forecast is the first quarter of 2022, a year later than the consensus. For Cronos CRON, -2.57% CRON, -2.61%, it’s the first quarter of 2023, compared with consensus for fourth quarter 2021, and for Hexo Corp. HEXO, -6.53%, his date is second quarter 2020, matching the consensus.

“With Aurora warning of slower buying from provinces in July and August (warning Sept. 12), and little indication new retail locations are opening in Ontario in October, we believe the next reported quarter will not show meaningful net sales acceleration,” Kirk wrote. “Increased costs, without the hoped for sequential revenue growth, results in profitability that is likely to disappoint.”

Don’t miss: Cannabis companies are having a horrible summer as scandals mount and stocks slide

For Canadian LPs to improve profitability would require that pricing holds up, that new products due at year-end when derivatives come on line succeed and are margin-accretive, that export markets demand product grown in Canada and that brands start to resonate across regions.

Read: Canopy Growth’s remaining CEO talks about pot company’s shake-up, and the search for his replacement

“Rather than be wildly profitable in two years, we expect the Canadian LPs to be roughly break-even,” said Kirk. They would need to keep their sales, general and admin. costs flat — which is unlikely — and that would barely produce the P&L leverage to reach consensus estimates. Companies would need to move from about C$500 million ($377 million) in EBITDA losses in the current year to a C$900mn EBITDA gain in two years.

By comparison, the U.S. government has calculated that Mexican cartel chief El Chapo (Joaquin Guzman) made over $12 billion from his illegal drug trade, while the top Canadian growers have cumulatively lost $1.4 billion, said Kirk.

Canopy stock was down 3%, Cronos was down 3%, Aurora was down 5%, Tilray was down 3% and Hexo was down 5%.

From Marijuana Business Daily comes the news that the wholesale cannabis market has remained largely unmoved by the current outbreak of severe lung disease that is believed to be tied to vaping. The disease, which has killed 12 people and sickened more than 800, according to the Centers for Disease Control and Prevention, was expected to discourage consumers from vaping cannabis products and move them to flower and pre-rolls instead. But wholesale cannabis growers said pricing has not moved dramatically during the crisis, and the percentage of flower being purchased has barely changed.

See now: Cannabis stocks mostly lower as euphoria over banking bill fades in face of tricky U.S. Senate path

In California, for example, the percentage of flower purchased as of Sept. 22 was 40.7%, down from 41.1% on Sept. 1. In Colorado, the percentage has climbed to 50.1% from 45.3%.

See now: Vape sales are falling on fears about the outbreak of vaping-related lung illness

In company news, Tilt Holdings TLLTF, +33.21% said it has negotiated an agreement with six of its remaining founders, under which they will forfeit all 60.2 million stock options granted at the time of the reverse merger of four companies that created Tilt last year.

Cannabis Watch: For all of MarketWatch’s coverage of cannabis companies

Tilt stock was last quoted at the stock trading at 27 cents, up about 25%. The company reported stock-based compensation expense of $47 million in the second quarter because of the stock options.

“Adjusting for the subsequent forfeiture, TILT’s Q2 2019 net loss of $48.9 million would have been almost entirely reduced, bringing the company close to break-even,” it said in a statement. Tilt made headlines in May when it booked a goodwill impairment charge of about $500 million in its first quarterly report after going public. That led to a massive loss of $554.5 million on sales of $5.7 million.

Chief Executive Alex Coleman told MarketWatch at the time that the charge was because the company used one methodology on Dec. 6, 2018, to value the companies that merged to form Tilt Holdings, and a different set of standards on Dec. 31.

For more on this, read: How a freshly grown cannabis company managed to lose $500 million in less than a month

Elsewhere in the sector, Organigram OGI, -3.67% fell 4%, Green Growth Brands GGBXF, -2.09% GGB, -0.81% was down 7% and Aleafia Health ALEAF, -3.42% ALEF, -3.33% was down 3%. Aphria Inc. APHA, +0.79% APHA, +0.90% was down 0.6%, MedMen MMNFF, -3.57% was down 0.4% and GW Pharma GWPH, -2.41% was down 4.3%.